Abstract

Background. Children with cancer have a higher morbidity and mortality due to COVID-19. Vaccination of children with cancer is important. In this study, we aimed to investigate the effectiveness and side effects of the COVID-19 vaccines in children and adolescents with cancer.

Methods. Fifty-eight patients from four centers were included in the study. Antibodies to the SARS-CoV-2 spike protein levels were measured. Vaccine-related complaints were recorded.

Results. There were 33 male and 25 female patients. The mean age was 16.9±2.3 years. In 58.6% of cases, the diagnosis was hematological malignancies. Twenty patients were currently under treatment, while 38 had completed the treatment. Forty-eight patients received chemotherapy ± radiotherapy, 13 received immunotherapy, and 3 underwent stem cell transplantation. CoronoVac© and BNT162b2© vaccines were administered in 24% and 76%, respectively. The mean antibody level was lower in patients who received CoronaVac© than that of BNT162b2©, although the difference was not significant. The levels were within the protective limits in both groups. No significant difference was found in antibody levels according to diagnostic subgroups, treatment status, type of treatment, line of treatment, disease status and time between vaccines and measurement of antibody level. The most common side effects were pain at the injection site (37.9%) and malaise/weakness (17.2%), which were similar for both vaccines.

Conclusions. Our study showed that both mRNA and inactivated vaccines elicit an immune response in children with cancer. However, the seroconversion rate is significantly higher in mRNA vaccines. Side effects were similar to those seen in healthy children. 

Keywords: cancer, COVID-19, vaccines, immunization

Copyright and license

Copyright © 2024 The Author(s). This is an open access article distributed under the Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Kurucu N, Kutluk T, Kartal İ, et al. Safety and efficacy of COVID-19 vaccines in children and adolescents with cancer. Turk J Pediatr 2024; 66: 412-420. https://doi.org/10.24953/turkjpediatr.2024.4512

References

  1. World Health Organization (WHO). Coronavirus disease (COVID-19) pandemic: WHO Coronavirus (COVID-19) Dashboard. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (Accessed on March 23, 2023).
  2. Republic of Türkiye Ministry of Health. COVID-19 information platform. Available at: https://covid19.saglik.gov.tr/TR-66935/genel-koronavirus-tablosu.html (Accessed on March 23, 2023).
  3. Habet V, Oliveira CR. Clinical epidemiology of pediatric Coronavirus disease 2019 and its postacute sequelae. Semin Respir Crit Care Med 2023; 44: 66-74. https://doi.org/10.1055/s-0042-1759566
  4. Gupta SL, Tyagi R, Dhar A, Oswal N, Khandelwal A, Jaiswal RK. Children's SARS-CoV-2 infection and their vaccination. Vaccines (Basel) 2023; 11: 418. https://doi.org/10.3390/vaccines11020418
  5. Saini KS, Tagliamento M, Lambertini M, et al. Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies. Eur J Cancer 2020; 139: 43-50. https://doi.org/10.1016/j.ejca.2020.08.011
  6. Mukkada S, Bhakta N, Chantada GL, et al. Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study. Lancet Oncol 2021; 22: 1416-1426. https://doi.org/10.1016/S1470-2045(21)00454-X
  7. Kebudi R, Kurucu N, Tuğcu D, et al. COVID-19 infection in children with cancer and stem cell transplant recipients in Turkey: a nationwide study. Pediatr Blood Cancer 2021; 68: e28915. https://doi.org/10.1002/pbc.28915
  8. National Institutes of Health. COVID-19 treatment guidelines panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. Available at: https://www.covid19treatmentguidelines.nih.gov (Accessed on March 23, 2023).
  9. Basta NE, Moodie EMM on behalf of the VIPER (Vaccines, Infectious disease Prevention, and Epidemiology Research) Group COVID-19 Vaccine Development and Approvals Tracker Team. COVID-19 vaccine development and approvals tracker. 2020. Available at: https://covid19.trackvaccines.org
  10. National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases. CDC COVID-19 Science Briefs. Atlanta (GA): Centers for Disease Control and Prevention (US); 2020-2021 Sep 15. Available at: https://www.ncbi.nlm.nih.gov/books/NBK570439/
  11. Republic of Türkiye Ministry of Health. COVID-19 vaccines information platform. Available at: https://covid19asi.saglik.gov.tr/TR-77706/covid-19-asisi-ulusal-uygulama-stratejisi.html (Accessed on March 23, 2023).
  12. Hause AM, Baggs J, Marquez P, et al. COVID-19 vaccine safety in children aged 5-11 Years - United States, November 3-December 19, 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 1755-1760. https://doi.org/10.15585/mmwr.mm705152a1
  13. Tian F, Yang R, Chen Z. Safety and efficacy of COVID-19 vaccines in children and adolescents: a systematic review of randomized controlled trials. J Med Virol 2022; 94: 4644-4653. https://doi.org/10.1002/jmv.27940
  14. Bozzola E, Caffarelli C, Santamaria F, Corsello G. The year 2021 in COVID-19 pandemic in children. Ital J Pediatr 2022; 48: 161. https://doi.org/10.1186/s13052-022-01360-0
  15. Gao P, Kang LY, Liu J, Liu M. Immunogenicity, effectiveness, and safety of COVID-19 vaccines among children and adolescents aged 2-18 years: an updated systematic review and meta-analysis. World J Pediatr 2023; 19: 1041-1054. https://doi.org/10.1007/s12519-022-00680-9
  16. Kuderer NM, Hill JA, Carpenter PA, Lyman GH. Challenges and opportunities for COVID-19 vaccines in patients with cancer. Cancer Invest 2021; 39: 205-213. https://doi.org/10.1080/07357907.2021.1885596
  17. Massarweh A, Eliakim-Raz N, Stemmer A, et al. Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer. JAMA Oncol 2021; 7: 1133-1140. https://doi.org/10.1001/jamaoncol.2021.2155
  18. Caniza MA, Homsi MR, Bate J, et al. Answers to common questions about COVID-19 vaccines in children with cancer. Pediatr Blood Cancer 2022; 69: e29985. https://doi.org/10.1002/pbc.29985
  19. Furlong E, Kotecha RS, Conyers R, et al. COVID-19 vaccination in children and adolescents aged 5 years and older undergoing treatment for cancer and non-malignant haematological conditions: Australian and New Zealand Children's Haematology/Oncology Group consensus statement. Med J Aust 2022; 216: 312-319. https://doi.org/10.5694/mja2.51444
  20. Kaltsas A, Sepkowitz K. Community acquired respiratory and gastrointestinal viral infections: challenges in the immunocompromised host. Curr Opin Infect Dis 2012; 25: 423-430. https://doi.org/10.1097/QCO.0b013e328355660b
  21. Miao J, Zhang JY, Liang J, et al. Efficacy of inactivated SARS-CoV-2 vaccination in pediatric hematology/oncology patients: a real-world study. World J Pediatr 2023; 19: 1017-1021. https://doi.org/10.1007/s12519-023-00737-3
  22. Poparn H, Srichumpuang C, Sosothikul D, et al. Immune response after 2 doses of BNT162b2 mRNA COVID-19 vaccinations in children and adolescents with cancer and hematologic diseases. Asian Pac J Cancer Prev 2022; 23: 2049-2055. https://doi.org/10.31557/APJCP.2022.23.6.2049
  23. Revon-Riviere G, Ninove L, Min V, et al. The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: a monocentric experience. Eur J Cancer 2021; 154: 30-34. https://doi.org/10.1016/j.ejca.2021.06.002
  24. Donze C, Ninove L, de Lamballerie X, Saultier P, Andre N. Six-month BNT162b2 vaccine efficacy in adolescents and young adults with cancer. Pediatr Blood Cancer 2022; 69: e29547. https://doi.org/10.1002/pbc.29547
  25. Lehrnbecher T, Sack U, Speckmann C, et al. Longitudinal immune response to 3 doses of messenger RNA vaccine against Coronavirus disease 2019 (COVID-19) in pediatric patients receiving chemotherapy for cancer. Clin Infect Dis 2023; 76: e510-e513. https://doi.org/10.1093/cid/ciac570
  26. Schmidt KLJ, Dautzenberg NMM, Hoogerbrugge PM, et al. Immune response following BNT162b2 mRNA COVID-19 vaccination in pediatric cancer patients. Cancers (Basel) 2023; 15: 2562. https://doi.org/10.3390/cancers15092562
  27. D'Souza AM, Thomas M, Gnanamony M, Nguyen TH, de Alarcon PA. SARS-CoV-2 vaccination response in pediatric oncology patients. Pediatr Blood Cancer 2024; 71: e30785. https://doi.org/10.1002/pbc.30785
  28. Ma Y, Chen B, Wang Y, et al. Reducedhumoral response against variants of concern in childhood solid cancer patients compared to adult patients and healthy children after SARS-CoV-2 vaccination. Front Immunol 2023; 14: 1110755. https://doi.org/10.3389/fimmu.2023.1110755
  29. Martin SD, Nziza N, Miozzo P, et al. Humoral profiling of pediatric patients with cancer reveals robust immunity following anti-SARS-CoV-2 vaccination superior to natural infection. Pediatr Blood Cancer 2023; 70: e30473. https://doi.org/10.1002/pbc.30473